Clinical Trials Directory

Trials / Sponsors / Janssen Infectious Diseases BVBA

Janssen Infectious Diseases BVBA

Industry · 14 registered clinical trials.

StatusTrialPhaseStarted
CompletedA Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspensi
Human Immunodeficiency Virus Type 1
Phase 12015-08-14
CompletedA Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Pa
Healthy
Phase 12015-05-01
CompletedA Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir
Healthy
Phase 12014-07-01
CompletedEfficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis
Hepatitis C Virus Infection
Phase 32014-04-01
CompletedEfficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic
Hepatitis C Virus Infection
Phase 32014-04-01
WithdrawnA Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Res
Multi-drug Resistant Tuberculosis
Phase 32014-03-01
CompletedA Study to Assess the Relative Bioavailability of TMC207 Following Single-Dose Administrations of Two Pediatri
Healthy, Biological Availability
Phase 12013-04-01
CompletedA Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment
Hepatic Impairment
Phase 12012-06-01
CompletedA Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telap
Healthy Participants
Phase 12012-05-01
CompletedVX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Parti
Genotype 1 Chronic Hepatitis C, Treatment Naive
Phase 32010-12-01
CompletedVX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telapre
Hepatitis C, Chronic
Phase 32010-04-01
CompletedTo Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant
Tuberculosis
Phase 22009-09-01
CompletedTMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-dru
Tuberculosis
Phase 22007-06-01
Approved For MarketingEarly Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis
Tuberculosis
——